Symbols / COGT Stock $36.81 +1.85% Cogent Biosciences, Inc.

Healthcare • Biotechnology • United States • NMS
COGT (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Andrew R. Robbins M.B.A.
Exch · Country NMS · United States
Market Cap 6.29B
Enterprise Value 5.36B
Income -328.94M
Sales —
FCF (ttm) -152.49M
Book/sh 3.40
Cash/sh 5.59
Employees 258
Insider 10d —
IPO Mar 29, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -53.44
PEG —
P/S —
P/B 10.84
P/C —
EV/EBITDA -16.19
EV/Sales —
Quick Ratio 14.09
Current Ratio 14.23
Debt/Eq 37.52
LT Debt/Eq —
EPS (ttm) -2.16
EPS next Y -0.69
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-05
Earnings (prior) 2026-02-17
ROA -32.93%
ROE -73.70%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 170.80M
Shs Float 150.97M
Insider Own 0.29%
Instit Own 103.29%
Short Float 7.09%
Short Ratio 4.69
Short Interest 12.04M
52W High 43.73
vs 52W High -15.82%
52W Low 4.55
vs 52W Low 709.01%
Beta 0.47
Impl. Vol. 63.28%
Rel Volume 0.57
Avg Volume 2.00M
Volume 1.14M
Target (mean) $54.17
Tgt Median $55.00
Tgt Low $35.00
Tgt High $72.00
# Analysts 12
Recom Strong_buy
Prev Close $36.14
Price $36.81
Change 1.85%
About

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$54.17
Mean price target
2. Current target
$36.81
Latest analyst target
3. DCF / Fair value
$-16.07
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$36.81
Low
$35.00
High
$72.00
Mean
$54.17

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-17 reit Wedbush Outperform → Outperform $55
2026-02-18 main Piper Sandler Overweight → Overweight $52
2026-01-21 reit Wedbush Outperform → Outperform $55
2026-01-06 main HC Wainwright & Co. Buy → Buy $52
2025-12-19 main JP Morgan Overweight → Overweight $67
2025-12-08 reit Needham Hold → Hold —
2025-11-13 main HC Wainwright & Co. Buy → Buy $50
2025-11-11 main Baird Neutral → Neutral $34
2025-11-10 main Leerink Partners Outperform → Outperform $50
2025-11-04 reit HC Wainwright & Co. Buy → Buy $21
2025-10-21 main JP Morgan Overweight → Overweight $44
2025-10-16 init Stifel — → Hold $16
2025-09-03 init Raymond James — → Strong Buy $30
2025-08-25 main Guggenheim Buy → Buy $20
2025-08-07 main JP Morgan Overweight → Overweight $30
2025-08-06 main HC Wainwright & Co. Buy → Buy $21
2025-07-18 main Citigroup Buy → Buy $22
2025-07-10 main JP Morgan Overweight → Overweight $29
2025-07-08 main HC Wainwright & Co. Buy → Buy $22
2025-07-08 reit Guggenheim Buy → Buy $17
News
RSS: Latest COGT news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-22 FAIRMOUNT FUNDS MANAGEMENT LLC Director — 3,500,000 $36.40 $127,400,000
2025-12-26 KEARNS EVAN D J.D. Officer — 65,000 $38.70 $2,515,500
2025-12-26 GREEN JOHN L Chief Financial Officer — 77,000 $38.68 $2,978,360
2025-12-26 SACHS JESSICA M.D. Officer — 82,642 $38.70 $3,198,245
2025-12-26 ROBINSON JOHN EDWARD Officer — 90,000 $38.74 $3,486,600
2025-12-17 ROBBINS ANDREW R. Chief Executive Officer — 1,025,000 $0.00 $0
2025-12-17 KEARNS EVAN D J.D. Officer — 300,000 $0.00 $0
2025-12-17 GREEN JOHN L Chief Financial Officer — 350,000 $0.00 $0
2025-12-17 SACHS JESSICA M.D. Officer — 370,000 $0.00 $0
2025-12-17 ROBINSON JOHN EDWARD Officer — 370,000 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
333.36
+20.81%
275.94
+32.58%
208.13
+40.78%
147.84
Research And Development
269.78
+15.96%
232.66
+33.90%
173.75
+42.86%
121.63
Selling General And Administration
63.58
+46.91%
43.28
+25.91%
34.38
+31.14%
26.21
General And Administrative Expense
63.58
+46.91%
43.28
+25.91%
34.38
+31.14%
26.21
Other Gand A
63.58
+46.91%
43.28
+25.91%
34.38
+31.14%
26.21
Total Expenses
333.36
+20.81%
275.94
+32.58%
208.13
+40.78%
147.84
Operating Income
-333.36
-20.81%
-275.94
-32.58%
-208.13
-40.78%
-147.84
Total Operating Income As Reported
-333.36
-20.81%
-275.94
-32.58%
-208.13
-40.78%
-147.84
EBITDA
-321.29
-27.75%
-251.51
-33.20%
-188.82
-33.01%
-141.96
Normalized EBITDA
-314.11
-24.89%
-251.51
-33.20%
-188.82
-33.01%
-141.96
Reconciled Depreciation
4.58
+5.33%
4.35
+21.27%
3.59
-38.96%
5.88
EBIT
-325.88
-27.37%
-255.86
-32.98%
-192.41
-30.15%
-147.84
Total Unusual Items
-7.18
0.00
0.00
—
Total Unusual Items Excluding Goodwill
-7.18
0.00
0.00
—
Special Income Charges
-7.18
0.00
0.00
—
Other Special Charges
7.18
—
—
—
Net Income
-328.94
-28.56%
-255.86
-32.98%
-192.41
-37.20%
-140.24
Pretax Income
-328.94
-28.56%
-255.86
-32.98%
-192.41
-37.20%
-140.24
Net Non Operating Interest Income Expense
11.63
-35.72%
18.09
+38.32%
13.08
+227.83%
3.99
Interest Expense Non Operating
3.06
0.00
0.00
—
Net Interest Income
11.63
-35.72%
18.09
+38.32%
13.08
+227.83%
3.99
Interest Expense
3.06
0.00
0.00
—
Interest Income Non Operating
14.69
-18.79%
18.09
+38.32%
13.08
+227.83%
3.99
Interest Income
14.69
-18.79%
18.09
+38.32%
13.08
+227.83%
3.99
Other Income Expense
-7.20
-461.50%
1.99
-24.63%
2.64
-26.77%
3.61
Other Non Operating Income Expenses
-0.02
-101.00%
1.99
-24.63%
2.64
-26.77%
3.61
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-328.94
-28.56%
-255.86
-32.98%
-192.41
-37.20%
-140.24
Net Income From Continuing Operation Net Minority Interest
-328.94
-28.56%
-255.86
-32.98%
-192.41
-37.20%
-140.24
Net Income From Continuing And Discontinued Operation
-328.94
-28.56%
-255.86
-32.98%
-192.41
-37.20%
-140.24
Net Income Continuous Operations
-328.94
-28.56%
-255.86
-32.98%
-192.41
-37.20%
-140.24
Normalized Income
-321.76
-25.76%
-255.86
-32.98%
-192.41
-37.20%
-140.24
Net Income Common Stockholders
-328.94
-28.56%
-255.86
-32.98%
-192.41
-37.20%
-140.24
Diluted EPS
—
-2.32
+4.29%
-2.42
-1.26%
-2.39
Basic EPS
—
-2.32
+4.29%
-2.42
-1.26%
-2.39
Basic Average Shares
—
110.46
+38.67%
79.66
+35.61%
58.74
Diluted Average Shares
—
110.46
+38.67%
79.66
+35.61%
58.74
Diluted NI Availto Com Stockholders
-328.94
-28.56%
-255.86
-32.98%
-192.41
-37.20%
-140.24
Gain On Sale Of PPE
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
937.61
+185.94%
327.90
+4.61%
313.44
+4.20%
300.81
Current Assets
910.36
+207.06%
296.47
+9.49%
270.77
+2.19%
264.97
Cash Cash Equivalents And Short Term Investments
900.76
+213.77%
287.08
+8.04%
265.71
+2.48%
259.28
Cash And Cash Equivalents
312.01
+217.84%
98.17
+84.42%
53.23
-61.95%
139.89
Other Short Term Investments
588.75
+211.65%
188.91
-11.09%
212.48
+77.97%
119.39
Prepaid Assets
—
—
—
4.43
Restricted Cash
—
—
0.00
-100.00%
1.25
Other Current Assets
9.59
+2.08%
9.39
+85.64%
5.06
+14.11%
4.43
Total Non Current Assets
27.25
-13.28%
31.43
-26.34%
42.67
+19.03%
35.84
Net PPE
23.54
-11.40%
26.56
-12.45%
30.34
-2.43%
31.10
Gross PPE
32.21
-1.42%
32.68
-3.91%
34.01
+4.64%
32.50
Accumulated Depreciation
-8.68
-41.93%
-6.12
-66.85%
-3.67
-161.60%
-1.40
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
18.08
-10.05%
20.10
-8.64%
22.00
-5.65%
23.32
Machinery Furniture Equipment
2.06
+3.41%
2.00
+4.50%
1.91
+34.53%
1.42
Construction In Progress
0.76
+1760.98%
0.04
+51.85%
0.03
-94.40%
0.48
Other Properties
8.85
+9.45%
8.08
+5.87%
7.63
+38.64%
5.51
Leases
2.46
+0.00%
2.46
+1.03%
2.44
+37.27%
1.78
Investments And Advances
—
0.00
-100.00%
7.46
0.00
Other Non Current Assets
3.72
-23.55%
4.86
-0.04%
4.86
+2.51%
4.75
Total Liabilities Net Minority Interest
301.24
+320.65%
71.61
+28.72%
55.63
+23.43%
45.08
Current Liabilities
63.95
+14.80%
55.71
+45.96%
38.17
+42.16%
26.85
Payables And Accrued Expenses
39.92
-3.83%
41.51
+56.85%
26.47
+53.35%
17.26
Payables
9.50
-20.89%
12.01
+12.75%
10.65
+82.39%
5.84
Accounts Payable
9.50
-20.89%
12.01
+12.75%
10.65
+82.39%
5.84
Current Accrued Expenses
30.42
+3.11%
29.50
+86.57%
15.81
+38.50%
11.42
Pensionand Other Post Retirement Benefit Plans Current
15.74
+28.40%
12.26
+24.15%
9.87
+62.86%
6.06
Current Debt And Capital Lease Obligation
1.55
-1.15%
1.56
+12.91%
1.39
-2.60%
1.42
Current Capital Lease Obligation
1.55
-1.15%
1.56
+12.91%
1.39
-2.60%
1.42
Current Deferred Liabilities
—
—
—
1.70
Current Deferred Revenue
—
—
—
1.70
Other Current Liabilities
6.75
+1708.31%
0.37
-15.42%
0.44
-79.04%
2.10
Total Non Current Liabilities Net Minority Interest
237.28
+1392.16%
15.90
-8.96%
17.47
-4.16%
18.23
Long Term Debt And Capital Lease Obligation
237.25
+1391.95%
15.90
-8.96%
17.47
-4.16%
18.23
Long Term Debt
222.90
—
—
—
Long Term Capital Lease Obligation
14.36
-9.73%
15.90
-8.96%
17.47
-4.16%
18.23
Other Non Current Liabilities
0.03
—
—
—
Stockholders Equity
636.37
+148.31%
256.29
-0.59%
257.80
+0.81%
255.74
Common Stock Equity
546.98
+275.45%
145.69
-26.33%
197.77
+4.14%
189.91
Capital Stock
89.55
-19.11%
110.71
+84.15%
60.12
-8.77%
65.90
Common Stock
0.16
+46.36%
0.11
+27.91%
0.09
+22.86%
0.07
Preferred Stock
89.39
-19.17%
110.60
+84.23%
60.03
-8.80%
65.83
Share Issued
160.98
+45.73%
110.46
+28.26%
86.12
+23.22%
69.89
Ordinary Shares Number
160.98
+45.73%
110.46
+28.26%
86.12
+23.22%
69.89
Additional Paid In Capital
1,734.88
+72.69%
1,004.61
+25.41%
801.06
+33.25%
601.15
Retained Earnings
-1,188.42
-38.27%
-859.48
-42.39%
-603.62
-46.79%
-411.21
Gains Losses Not Affecting Retained Earnings
0.35
-20.58%
0.45
+81.71%
0.25
+336.54%
-0.10
Other Equity Adjustments
0.35
-20.58%
0.45
+81.71%
0.25
+336.54%
-0.10
Total Equity Gross Minority Interest
636.37
+148.31%
256.29
-0.59%
257.80
+0.81%
255.74
Total Capitalization
859.27
+235.28%
256.29
-0.59%
257.80
+0.81%
255.74
Working Capital
846.40
+251.55%
240.76
+3.51%
232.60
-2.32%
238.12
Invested Capital
769.87
+428.45%
145.69
-26.33%
197.77
+4.14%
189.91
Total Debt
238.80
+1267.13%
17.47
-7.35%
18.85
-4.05%
19.65
Capital Lease Obligations
15.90
-8.96%
17.47
-7.35%
18.85
-4.05%
19.65
Net Tangible Assets
636.37
+148.31%
256.29
-0.59%
257.80
+0.81%
255.74
Tangible Book Value
546.98
+275.45%
145.69
-26.33%
197.77
+4.14%
189.91
Available For Sale Securities
—
—
7.46
—
Investmentin Financial Assets
—
0.00
-100.00%
7.46
0.00
Preferred Stock Equity
89.39
-19.17%
110.60
+84.23%
60.03
-8.80%
65.83
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-264.44
-27.26%
-207.79
-35.26%
-153.62
-29.49%
-118.64
Cash Flow From Continuing Operating Activities
-264.44
-27.26%
-207.79
-35.26%
-153.62
-29.49%
-118.64
Net Income From Continuing Operations
-328.94
-28.56%
-255.86
-32.98%
-192.41
-37.20%
-140.24
Depreciation Amortization Depletion
4.58
+5.33%
4.35
+21.27%
3.59
-38.96%
5.88
Depreciation
4.58
+5.33%
4.35
+21.27%
3.59
-38.96%
5.88
Depreciation And Amortization
4.58
+5.33%
4.35
+21.27%
3.59
-38.96%
5.88
Other Non Cash Items
0.60
—
-1.70
-25.00%
-1.36
Stock Based Compensation
46.08
+15.95%
39.74
+29.78%
30.62
+66.71%
18.37
Asset Impairment Charge
—
0.00
0.00
+100.00%
-0.40
Operating Gains Losses
7.18
—
0.01
—
Gain Loss On Sale Of PPE
0.00
0.00
-100.00%
0.01
0.00
Change In Working Capital
8.01
-30.92%
11.60
+1.35%
11.44
+1423.57%
0.75
Change In Receivables
—
—
—
—
Changes In Account Receivables
—
—
—
—
Change In Prepaid Assets
-0.20
+95.50%
-4.33
-592.33%
-0.63
+57.87%
-1.49
Change In Payables And Accrued Expense
8.18
-52.77%
17.31
+33.36%
12.98
+8.69%
11.95
Change In Accrued Expense
10.69
-33.03%
15.96
+95.30%
8.17
-14.77%
9.59
Change In Payable
-2.51
-284.76%
1.36
-71.78%
4.81
+104.03%
2.36
Change In Account Payable
-2.51
-284.76%
1.36
-71.78%
4.81
+104.03%
2.36
Change In Other Current Assets
1.56
+77950.00%
0.00
+101.68%
-0.12
+88.31%
-1.02
Change In Other Current Liabilities
-1.53
-10.53%
-1.39
-74.12%
-0.80
+90.84%
-8.69
Investing Cash Flow
-399.53
-1143.80%
38.28
+139.13%
-97.82
+21.56%
-124.72
Cash Flow From Continuing Investing Activities
-399.53
-1143.80%
38.28
+139.13%
-97.82
+21.56%
-124.72
Net PPE Purchase And Sale
-1.55
-171.20%
-0.57
+79.51%
-2.80
+59.26%
-6.86
Purchase Of PPE
-1.55
-171.20%
-0.57
+79.51%
-2.80
+59.26%
-6.86
Sale Of PPE
—
—
—
—
Capital Expenditure
-1.55
-171.20%
-0.57
+79.51%
-2.80
+59.26%
-6.86
Net Investment Purchase And Sale
-397.97
-1124.41%
38.85
+140.88%
-95.03
+19.37%
-117.86
Purchase Of Investment
-687.17
-168.84%
-255.60
+26.72%
-348.80
-96.12%
-177.85
Sale Of Investment
289.20
-1.78%
294.45
+16.03%
253.78
+322.96%
60.00
Financing Cash Flow
878.23
+309.53%
214.45
+31.13%
163.54
-0.01%
163.56
Cash Flow From Continuing Financing Activities
878.23
+309.53%
214.45
+31.13%
163.54
-0.01%
163.56
Net Issuance Payments Of Debt
217.76
0.00
0.00
—
Issuance Of Debt
272.39
0.00
0.00
—
Repayment Of Debt
-54.63
0.00
0.00
—
Long Term Debt Issuance
49.29
0.00
0.00
—
Long Term Debt Payments
-54.63
0.00
0.00
—
Net Long Term Debt Issuance
-5.34
0.00
0.00
—
Short Term Debt Issuance
223.10
0.00
0.00
—
Net Short Term Debt Issuance
223.10
0.00
0.00
—
Net Common Stock Issuance
159.32
-25.32%
213.34
+31.84%
161.82
-0.08%
161.94
Proceeds From Stock Option Exercised
552.67
+49467.00%
1.11
-35.06%
1.72
+6.45%
1.61
Net Other Financing Charges
-51.52
—
—
—
Changes In Cash
214.26
+376.82%
44.94
+151.11%
-87.91
-10.17%
-79.80
Beginning Cash Position
98.17
+84.42%
53.23
-62.29%
141.14
-36.12%
220.94
End Cash Position
312.43
+218.27%
98.17
+84.42%
53.23
-62.29%
141.14
Free Cash Flow
-266.00
-27.66%
-208.36
-33.21%
-156.42
-24.64%
-125.50
Interest Paid Supplemental Data
2.02
0.00
—
—
Amortization Of Securities
-1.96
+74.25%
-7.62
-47.28%
-5.17
-215.81%
-1.64
Common Stock Issuance
159.32
-25.32%
213.34
+31.84%
161.82
-0.08%
161.94
Issuance Of Capital Stock
159.32
-25.32%
213.34
+31.84%
161.82
-0.08%
161.94
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category